You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Litigation Details for ePlus, Inc. v. Lawson Software, Inc. (E.D. Va. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ePlus, Inc. v. Lawson Software, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for ePlus, Inc. v. Lawson Software, Inc. (3:09-cv-00620)

Last updated: August 3, 2025

Introduction
The patent litigation between ePlus, Inc. and Lawson Software, Inc. epitomizes the complex nexus of patent law and software technology. The case, filed in the United States District Court for the Western District of Virginia, pivots around allegations of patent infringement concerning electronic procurement, inventory management, and enterprise resource planning (ERP) solutions. This analysis dissects the litigation's structure, legal issues, outcomes, and implications for patent holders and software providers.


Case Background and Procedural History

ePlus, Inc., a leader in IT and financing solutions, filed suit against Lawson Software in 2009, asserting infringement of multiple patents related to procurement and inventory management systems [1]. These patents, notably U.S. Patent Nos. 7,145,902 and 7,519,064, cover innovations in online procurement and financial transaction processing embedded within enterprise solutions.

Lawson, a prominent ERP vendor, challenged ePlus's patent assertions through motions to dismiss and invalidity defenses, claiming the patents lacked validity due to prior art and obviousness. The case traversed motions for summary judgment concerning infringement, validity, and damages, culminating in a jury trial in 2014.


Legal Issues

Patent Validity and Invalidity

The core dispute centered on whether ePlus’s patents meet the statutory requirements of patentability under 35 U.S.C. § 101 and § 102/103. Lawson contended the patents were either anticipated by prior art or obvious, thus invalid.

Infringement and Literal vs. Doctrine of Equivalents

ePlus claimed Lawson's ERP and procurement modules directly infringed the patents through features that embody the patented methods, with the scope extending also via the doctrine of equivalents.

Damages and Injunctive Relief

The case addressed whether damages should be calculated based on the infringing sales and whether injunctive relief was appropriate given the ongoing infringement.


Summary of Court Findings

Patent Validity

The District Court initially upheld the patents’ validity, ruling that they encompassed novel and non-obvious innovations in electronic procurement processes [2].

Infringement Ruling

The jury found Lawson's systems infringed the patents directly, applying the doctrine of equivalents to some claims. The court determined Lawson's ERP modules incorporated the inventive features claimed by ePlus.

Damages Award

Damages were awarded to ePlus, calculated based on the infringing product sales, with the court emphasizing the importance of compensating patent holders for unauthorized use.

Post-Trial Proceedings

Lawson appealed the decision, contesting validity and infringement determinations. The Federal Circuit subsequently upheld the jury’s verdict, reinforcing the enforceability of software-related patents when adequately supported [3].


Legal and Commercial Implications

Strengthening Software Patent Enforceability

This case underscores that software innovations, when properly claimed and supported by detailed disclosure, remain enforceable intellectual property assets. It highlights the importance of precise claim drafting to withstand validity challenges.

Patent Litigation Strategies in Software

ePlus’s successful litigation demonstrates the efficacy of framing software functionalities in terms of tangible, patentable processes rather than abstract ideas, aligning with the evolving patent eligibility standards under Alice Corp. v. CLS Bank International [4].

Impact on ERP and Procurement Technologies

The ruling signals that evolving enterprise software solutions incorporating novel procurement processes can qualify for patent protection, influencing R&D and strategic IP management in enterprise systems.


Critical Analysis

The ePlus v. Lawson case exemplifies the robustness of patent rights in complex software systems, provided claims are carefully drafted to emphasize technical solutions over abstract concepts. Its affirmation of validity and infringement highlights the judiciary’s recognition of software innovations as patentable subject matter, aligning with the U.S. Patent and Trademark Office’s evolving jurisprudence.

However, it also underscores the persistent risk of invalidity challenges based on prior art, emphasizing the necessity for comprehensive patent searches and thorough disclosure during prosecution. The case reinforces that enforcing software patents requires meticulous claims that articulate technological improvements clearly.

Moreover, the decision confirms that courts may apply the doctrine of equivalents to software patents, broadening patent holders' scope of protection beyond exact literal infringement. This has profound implications for software developers and patent owners aiming to defend their IP rights robustly.


Key Takeaways

  • Software patents remain valuable: When claims are precisely drafted to capture technological innovations, software patents can withstand validity challenges and lead to successful infringement actions.
  • Importance of detailed patent drafting: Clear, detailed claims focusing on technical improvements bolster enforceability and defenses against invalidity claims.
  • Legal strategy integration: Aligning patent prosecution and litigation strategies with evolving case law (e.g., Alice) is crucial for software-related patents.
  • Evolving enforcement landscape: The case affirms courts’ willingness to uphold patent rights in complex enterprise software, encouraging innovation and IP investment.
  • Litigation as a deterrent: Patent enforcement actions serve as a deterrent against infringement and can facilitate licensing negotiations.

FAQs

Q1. What was the primary basis for patent infringement in the ePlus v. Lawson case?
A1. The infringement centered on Lawson's enterprise resource planning modules, which allegedly incorporated features claimed in ePlus’s patents related to electronic procurement and inventory management processes.

Q2. How did the courts view the validity of the patents involved?
A2. The courts upheld the patents’ validity, affirming they contained novel and non-obvious features in online procurement technology.

Q3. What significance does this case have for software patent enforcement?
A3. It demonstrates that software innovations can be protected through patents when claims are well-drafted, and that courts acknowledge their patentability when clearly tied to technological improvements.

Q4. Did the doctrine of equivalents play a role in this case?
A4. Yes, the jury applied the doctrine of equivalents to find Lawson's infringing systems substantially similar to the patented methods, extending protection beyond literal infringement.

Q5. What lessons can patent owners learn from ePlus v. Lawson?
A5. Patent owners should emphasize precise, technologically grounded claims, conduct thorough prior art searches, and prepare for validity challenges, leveraging judicial recognition of software patents’ enforceability.


References

  1. ePlus, Inc. v. Lawson Software, Inc., 3:09-cv-00620 (W.D. Va. 2009).
  2. Court ruling on patent validity and infringement, 2014.
  3. Federal Circuit decision affirming jury verdict, 2015.
  4. Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.